Itsa,
I agree but...….a bird in the hand is worth...………..two in the bush!
If Moses, Diamond and Goolsbee play the long game, the mind boggles re the valuation for ANP if we get approval in Europe or USA.
Sarepta were raking in $80m per quarter in revenue just by selling to 13% of patients.
ANP would be looking at market caps +$3B or +$6 per share...….pipe dream.
At the moment, Top 40 holders own over 52% of ANP.
If Platinum and AEF are onboard, you never know...the long game could play out.
Or they could just take the $2 takeover nugget in 2020 and be happy with unicorn status $1B market cap.
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-442
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |